FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896925652> ?p ?o ?g. }

• W2896925652 endingPage "427" @default.
• W2896925652 startingPage "422" @default.
• W2896925652 abstract "Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal or peritoneal cancer through the frequency of objective tumor responses (ORR).Patients with measurable disease, acceptable organ function, performance status ≤ 2, and one prior platinum containing regimen were eligible. A two-stage design was utilized with a target sample size of 22 and 30 subjects, respectively. Prior Gynecologic Oncology Group studies within the same population involving single agent taxanes showed an ORR of approximately (20%) and served as a historical control for direct comparison. The present study was designed to determine if the regimen had an ORR of ≥40% with 90% power.Fifty-eight patients were enrolled, of whom 2 received no study treatment and were inevaluable. The median number of cycles was 3 (268 total cycles, range 1-18). The number of patients responding was 11 (19.6%; 90% CI 11.4% to 30.4%) with one complete response. The median progression-free survival and overall survival was 3.6 months and 13.3 months, respectively. The median ORR duration was 9.2 months. Percentages of subjects with grade 3 toxicity included: Neutropenia 9%; anemia 5%; metabolic 5%; nausea 4%; infection 4%; neurologic (mostly neuropathy) 4%; and vascular (mostly thromboembolism) 4%. There were no grade 4 toxicities reported.This combination was well tolerated but is unworthy of further investigation based on the proportion responding [ClinicalTrials.gov Identifier: NCT00888615]." @default.
• W2896925652 created "2018-10-26" @default.
• W2896925652 creator A5004006667 @default.
• W2896925652 creator A5009155196 @default.
• W2896925652 creator A5014611244 @default.
• W2896925652 creator A5043474798 @default.
• W2896925652 creator A5054602117 @default.
• W2896925652 creator A5056632427 @default.
• W2896925652 creator A5062151371 @default.
• W2896925652 creator A5073422778 @default.
• W2896925652 creator A5081131995 @default.
• W2896925652 date "2018-12-01" @default.
• W2896925652 modified "2023-10-14" @default.
• W2896925652 title "A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study" @default.
• W2896925652 cites W1978407272 @default.
• W2896925652 cites W1984458529 @default.
• W2896925652 cites W2019607817 @default.
• W2896925652 cites W2029409133 @default.
• W2896925652 cites W2037282195 @default.
• W2896925652 cites W2041142804 @default.
• W2896925652 cites W2046940607 @default.
• W2896925652 cites W2068854353 @default.
• W2896925652 cites W2090859762 @default.
• W2896925652 cites W2095761326 @default.
• W2896925652 cites W2142043975 @default.
• W2896925652 cites W2170928115 @default.
• W2896925652 cites W2341250343 @default.
• W2896925652 cites W2394878602 @default.
• W2896925652 cites W2753722921 @default.
• W2896925652 doi "https://doi.org/10.1016/j.ygyno.2018.10.001" @default.
• W2896925652 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6392076" @default.
• W2896925652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30309721" @default.
• W2896925652 hasPublicationYear "2018" @default.
• W2896925652 type Work @default.
• W2896925652 sameAs 2896925652 @default.
• W2896925652 citedByCount "39" @default.
• W2896925652 countsByYear W28969256522019 @default.
• W2896925652 countsByYear W28969256522020 @default.
• W2896925652 countsByYear W28969256522021 @default.
• W2896925652 countsByYear W28969256522022 @default.
• W2896925652 countsByYear W28969256522023 @default.
• W2896925652 crossrefType "journal-article" @default.
• W2896925652 hasAuthorship W2896925652A5004006667 @default.
• W2896925652 hasAuthorship W2896925652A5009155196 @default.
• W2896925652 hasAuthorship W2896925652A5014611244 @default.
• W2896925652 hasAuthorship W2896925652A5043474798 @default.
• W2896925652 hasAuthorship W2896925652A5054602117 @default.
• W2896925652 hasAuthorship W2896925652A5056632427 @default.
• W2896925652 hasAuthorship W2896925652A5062151371 @default.
• W2896925652 hasAuthorship W2896925652A5073422778 @default.
• W2896925652 hasAuthorship W2896925652A5081131995 @default.
• W2896925652 hasBestOaLocation W28969256521 @default.
• W2896925652 hasConcept C121608353 @default.
• W2896925652 hasConcept C126322002 @default.
• W2896925652 hasConcept C141071460 @default.
• W2896925652 hasConcept C143998085 @default.
• W2896925652 hasConcept C2775883341 @default.
• W2896925652 hasConcept C2776694085 @default.
• W2896925652 hasConcept C2777063308 @default.
• W2896925652 hasConcept C2780427987 @default.
• W2896925652 hasConcept C2780435969 @default.
• W2896925652 hasConcept C2780580376 @default.
• W2896925652 hasConcept C2780739268 @default.
• W2896925652 hasConcept C2781413609 @default.
• W2896925652 hasConcept C2908647359 @default.
• W2896925652 hasConcept C31760486 @default.
• W2896925652 hasConcept C71924100 @default.
• W2896925652 hasConcept C99454951 @default.
• W2896925652 hasConceptScore W2896925652C121608353 @default.
• W2896925652 hasConceptScore W2896925652C126322002 @default.
• W2896925652 hasConceptScore W2896925652C141071460 @default.
• W2896925652 hasConceptScore W2896925652C143998085 @default.
• W2896925652 hasConceptScore W2896925652C2775883341 @default.
• W2896925652 hasConceptScore W2896925652C2776694085 @default.
• W2896925652 hasConceptScore W2896925652C2777063308 @default.
• W2896925652 hasConceptScore W2896925652C2780427987 @default.
• W2896925652 hasConceptScore W2896925652C2780435969 @default.
• W2896925652 hasConceptScore W2896925652C2780580376 @default.
• W2896925652 hasConceptScore W2896925652C2780739268 @default.
• W2896925652 hasConceptScore W2896925652C2781413609 @default.
• W2896925652 hasConceptScore W2896925652C2908647359 @default.
• W2896925652 hasConceptScore W2896925652C31760486 @default.
• W2896925652 hasConceptScore W2896925652C71924100 @default.
• W2896925652 hasConceptScore W2896925652C99454951 @default.
• W2896925652 hasFunder F4320337351 @default.
• W2896925652 hasIssue "3" @default.
• W2896925652 hasLocation W28969256521 @default.
• W2896925652 hasLocation W28969256522 @default.
• W2896925652 hasLocation W28969256523 @default.
• W2896925652 hasLocation W28969256524 @default.
• W2896925652 hasOpenAccess W2896925652 @default.
• W2896925652 hasPrimaryLocation W28969256521 @default.
• W2896925652 hasRelatedWork W1965594374 @default.
• W2896925652 hasRelatedWork W1978453679 @default.
• W2896925652 hasRelatedWork W1979130534 @default.
• W2896925652 hasRelatedWork W2020898191 @default.
• W2896925652 hasRelatedWork W2030410367 @default.
• W2896925652 hasRelatedWork W2362108816 @default.

• next